度洛西汀治疗抑郁伴焦虑障碍患者的随机双盲对照研究

A randomized, double-blind controlled study on efficacy of duloxetine and paroxitine in treatment of co-occurring depression and anxiety disorder

目的比较度洛西汀与帕罗西汀治疗抑郁伴焦虑障碍的疗效和安全性。方法对24例符合CCMD-3抑郁发作和广泛性焦虑诊断标准的患者随机双盲进入度洛西汀或帕罗西汀组治疗6周，分别在治疗前及第1、2、4、6周末进行汉密尔顿抑郁量表17项（HAMD）、汉密尔顿焦虑量表（HAMA）和临床疗效总评量表的病情严重程度（CGI-SI）评定，进行体格检查、实验室检查，及采用副反应量表（TESS）评估用药安全性。结果经6周治疗后显示，度洛西汀总体疗效比帕罗西汀稍好且起效快，效果良好，在治疗第1周末HAMD总分与帕罗西汀组有显著性差异（P〈0.05）。两组不良反应均较轻微。结论度洛西汀抗抑郁及抗焦虑作用确切，可用于治疗抑郁症伴焦虑障碍。

Objective To control the efficacy of duloxetine and paroxetine in treatment of co occurring depression and anxiety disorder. Methods 24 patients with a diagnosis of major depressive episode and anxiety disorder （CCMD 3） were randomly assigned to 6 weeks of treatment with duloxetine or paroxetine in double-blind. The efficacy was assessed with HAMD-17, HAMA and CGI SI at the end of baseline and 1,2,4,6 weeks after treatment. Safety was estimated by TESS 6 weeks treatment, the result based on the laboratory and physical examination. Results After reduction rate of HAMD and HAMA showed duloxetine was comparably effective as paroxetine. The HAMD scores decreased significantly at the end of 1 week after treatment between two groups （P〈0.05）. The adverse effects were mild. Conclusions Duloxetine has positive effectiveness in co-occurring depression and anxiety disorder.